First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses

OBJECTIVES: Phosphatidylcholine is a key component of the mucosal barrier. Treatment with modified release phosphatidylcholine aims to improve the impaired barrier function. The primary objective is to evaluate the efficacy of LT-02, a newly designed modified release phosphatidylcholine formula, in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Karner, Max, Kocjan, Andreas, Stein, Juergen, Schreiber, Stefan, von Boyen, Georg, Uebel, Peter, Schmidt, Carsten, Kupcinskas, Limas, Dina, Ion, Zuelch, Frank, Keilhauer, Gerhard, Stremmel, Wolfgang
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2014
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4085478/
https://ncbi.nlm.nih.gov/pubmed/24796768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ajg.2014.104
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares